Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR

BACKGROUND. This phase II single-arm trial evaluated afatinib, an irreversible inhibitor of the ErbB receptor family as third-line treatment of Korean patients with advanced non-small cell lung cancer (NSCLC) and tumors with wild-type EGFR. Currently, no standard therapy exists for these patients. M...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ahn, Myung-Ju, Kim, Sang-We, Cho, Byoung-Chul, Ahn, Jin Seok, Lee, Dae Ho, Sun, Jong-Mu, Massey, Dan, Kim, Miyoung, Shi, Yang, Park, Keunchil
Formato: Artigo
Lenguaje:Inglês
Publicado: AlphaMed Press 2014
Materias:
Clinical Trial Results
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4077442/
https://ncbi.nlm.nih.gov/pubmed/24868099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0419
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares